Davis Polk advised the lead book-running manager and representative of the underwriters in connection with its $101.9 million initial public offering of common stock of Jounce Therapeutics, Inc. The common stock is listed on NASDAQ Global Select Market under the symbol “JNCE.”

Based in Cambridge, Massachusetts, Jounce is a clinical stage immunotherapy company dedicated to transforming the treatment of cancer by developing therapies that enable the immune system to attack tumors and provide long-lasting benefits to patients. Through the use of its Translational Science Platform, Jounce first focuses on specific cell types within tumors to prioritize targets, and then identifies related biomarkers designed to match the right therapy to the right patient. Jounce was launched in 2013 with funding from leading life sciences investor, Third Rock Ventures. In July 2016, Jounce announced a global strategic collaboration with Celgene Corporation.

The Davis Polk corporate team included partner Deanna L. Kirkpatrick and associates Yasin Keshvargar and John H. Runne. Counsel David R. Bauer and associate Bonnie Chen provided intellectual property and technology advice. Counsel Marcie A. Goldstein provided FINRA advice. All members of the Davis Polk team are based in the New York office.

Copy link to share post